The investment to expand manufacturing at Pfizer’s plant in Dublin would double its capacity to produce key substances used in biological drugs.
The near year-long infant formula shortage in the United States that prompted the intervention of the White House is likely to “persist” until spring, according to Reckitt Benckiser, the maker of what is now the biggest brand in the market, Enfamil.
Under the terms, biotech firm Roivant will be responsible for funding the development and will retain commercialization rights for RVT-3101, once approved, in the United States and Japan.
The Ireland-based company issued a statement confirming that it is engaged in “highly preliminary discussions” with Amgen, Janssen, and Sanofi. Any acquisition of Horizon Therapeutics would be among the biggest deals of 2022.
The drug is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron.
Johnson & Johnson’s Janssen unit has sued Amgen Inc. over its plan to market a drug for ulcerative colitis and other conditions similar to J&J’s Stelara, saying it would infringe two patents in a lawsuit made public on Wednesday.
Nimbus Therapeutics reported positive Phase IIb results on Wednesday for its TYK2 inhibitor, NDI-034858, in moderate-to-severe plaque psoriasis.
Full data presented Tuesday afternoon from the Phase III Clarity AD trial show Eisai and Biogen’s lecanemab has a favorable safety profile in patients with Alzheimer’s disease.
The number of people in Europe with undiagnosed HIV has risen as testing rates fell during the COVID-19 pandemic, threatening a global goal of ending the disease by 2030, a report said.
Britain is only marginally better prepared for another pandemic than it was for COVID-19, the former head of Britain’s vaccine taskforce said on Wednesday, criticizing how some structures that helped it emerge from the pandemic had been dismantled.